Cequent releases primate safety, efficacy data for oral FAP therapy

News | 02. 12. 2009

Cequent Pharmaceuticals

February 12, 2009

Cequent Pharmaceuticals this week unveiled non-human primate data demonstrating the safety and gene-silencing ability of its lead drug candidate, a treatment for familial adenomatous polyposis dubbed CEQ501, in what the company is calling the first proof of activity of an oral RNAi drug.